Whole animal automated platform for drug discovery against multi-drug resistant staphylococcus aureus

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Rajamuthiah, Rajmohan ^a,b   Fuchs, Beth Burgwyn ^a,b   Jayamani, Elamparithi ^a,b   Kim, Younghoon ^c   Larkins Ford, Jonah ^b   Conery, Annie ^b   Ausubel, Frederick M ^b   Mylonakis, Eleftherios ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CEFOTAXIME; CLINAFLOXACIN; CLINDAMYCIN; CLOSANTEL; DOXYCYCLINE; ENOXACIN; ENROFLOXACIN; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOMYCIN; LINEZOLID; LOMEFLOXACIN; MINOCYCLINE; NADIFLOXACIN; NORDIFLOXACIN; NOVOBIOCIN; OFLOXACIN; PAZUFLOXACIN; PEFLOXACIN; RIFAMPICIN; RIFAMYCIN; ROXITHROMYCIN; RUFLOXACIN; SPARFLOXACIN; TOSUFLOXACIN; TROLEANDOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; ASSAY; AUTOMATION; BACTERIAL VIRULENCE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG SCREENING; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; IMAGE ANALYSIS; LIQUID INFECTION ASSAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY; MULTIDRUG RESISTANCE; NONHUMAN; ROBOTICS; STAPHYLOCOCCUS AUREUS; SURVIVAL; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CAENORHABDITIS ELEGANS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SALICYLANILIDES; SMALL MOLECULE LIBRARIES;

EID: 84896751347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089189     Document Type: Article

References (74)

1. Boucher HW, Corey GR (2008) Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5: S344-349. (Pubitemid 351717321)
2. Jones RN (2003) Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 24: 121-134.
3. Gottlieb GS, Fowler VG Jr, Kong LK, McClelland RS, Gopal AK, et al. (2000) Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. J Am Coll Surg 190: 50-57. (Pubitemid 30020576)
4. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, et al. (2007) Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 13: 257-263. (Pubitemid 46603355)
5. Feng Y, Chen CJ, Su LH, Hu S, Yu J, et al. (2008) Evolution and pathogenesis of Staphylococcus aureus: lessons learned from genotyping and comparative genomics. FEMS Microbiol Rev 32: 23-37. (Pubitemid 350293912)
6. Lindsay JA (2010) Genomic variation and evolution of Staphylococcus aureus. Int J Med Microbiol 300: 98-103.
7. Cuddy SM (2008) Methicillin-resistant Staphylococcus aureus: a new pandemic? Plast Surg Nurs 28: 168-169.
8. Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109.
9. Sifri CD, Begun J, Ausubel FM (2005) The worm has turned-microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol 13: 119-127. (Pubitemid 40311894)
10. Mylonakis E, Casadevall A, Ausubel FM (2007) Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog 3: e101.
11. Sifri CD, Begun J, Ausubel FM, Calderwood SB (2003) Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect Immun 71: 2208-2217. (Pubitemid 36368756)
12. Irazoqui JE, Troemel ER, Feinbaum RL, Luhachack LG, Cezairliyan BO, et al. (2010) Distinct pathogenesis and host responses during infection of C. elegans by P. aeruginosa and S. aureus. PLoS Pathog 6: e1000982.
13. Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, et al. (2002) A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297: 623-626. (Pubitemid 34815350)
14. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359: 1819-1827. (Pubitemid 34607058)
15. Fox PM, Lampen RJ, Stumpf KS, Archer GL, Climo MW (2006) Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother 50: 2951-2956. (Pubitemid 44396397)
16. Campbell J, Singh AK, Santa Maria JP, Jr., Kim Y, Brown S, et al. (2011) Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem Biol 6: 106-116.
17. Tan MW, Mahajan-Miklos S, Ausubel FM (1999) Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci U S A 96: 715-720. (Pubitemid 29061274)
18. Beanan MJ, Strome S (1992) Characterization of a germ-line proliferation mutation in C. elegans. Development 116: 755-766.
19. Tanaka-Hino M, Sagasti A, Hisamoto N, Kawasaki M, Nakano S, et al. (2002) SEK-1 MAPKK mediates Ca2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans. EMBO Rep 3: 56-62. (Pubitemid 34144816)
20. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73. (Pubitemid 29278954)
21. Fuchs S, Pane-Farre J, Kohler C, Hecker M, Engelmann S (2007) Anaerobic gene expression in Staphylococcus aureus. J Bacteriol 189: 4275-4289. (Pubitemid 46847376)
22. Powell JR, Ausubel FM (2008) Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. Methods Mol Biol 415: 403-427.
23. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, et al. (2011) Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27: 1179-1180.
24. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, et al. (2009) High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 4: 527-533.
25. Jorgensen JH, Ferraro MJ (2009) Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis 49: 1749-1755.
26. Day SR, Moore CM, Kundzins JR, Sifri CD (2012) Community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus virulence toward Caenorhabditis elegans compared. Virulence 3: 576-582.
27. Yang J, Chen Z, Ching P, Shi Q, Li X (2013) An integrated microfluidic platform for evaluating in vivo antimicrobial activity of natural compounds using a whole-animal infection model. Lab Chip 13: 3373-3382.
28. Begun J, Sifri CD, Goldman S, Calderwood SB, Ausubel FM (2005) Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infect Immun 73: 872-877. (Pubitemid 40165745)
29. Sifri CD, Baresch-Bernal A, Calderwood SB, von Eiff C (2006) Virulence of Staphylococcus aureus small colony variants in the Caenorhabditis elegans infection model. Infect Immun 74: 1091-1096. (Pubitemid 43185546)
30. Wu K, Simor AE, Vearncombe M, McClure JA, Zhang K (2012) A Caenorhabditis elegans host model correlates with invasive disease caused by Staphylococcus aureus recovered during an outbreak in neonatal intensive care. Can J Infect Dis Med Microbiol 23: 130-134.
31. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, et al. (2001) A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci U S A 98: 10892-10897. (Pubitemid 32878715)
32. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, et al. (2006) Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103: 10414-10419. (Pubitemid 44051181)
33. Kirienko NV, Kirienko DR, Larkins-Ford J, Wahlby C, Ruvkun G, et al. (2013) Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death. Cell Host Microbe 13: 406-416.
34. Van Voorhies WA, Ward S (2000) Broad oxygen tolerance in the nematode Caenorhabditis elegans. J Exp Biol 203: 2467-2478.
35. Suzuki T, Campbell J, Kim Y, Swoboda JG, Mylonakis E, et al. (2012) Wall teichoic acid protects Staphylococcus aureus from inhibition by Congo red and other dyes. J Antimicrob Chemother 67: 2143-2151.
36. Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, et al. (2012) Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids. Proc Natl Acad Sci U S A 109: 18909-18914.
37. Kielhofner MA (1990) Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex Heart Inst J 17: 86-93. (Pubitemid 20214741)
38. Mulazimoglu L, Drenning SD, Muder RR (1996) Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin- resistant Staphylococcus aureus. Antimicrob Agents Chemother 40: 1534-1535. (Pubitemid 26169063)
39. Hall WH, Opfer BJ, Gerding DN (1980) Comparative activities of the oxa-betalactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother 17: 273-279. (Pubitemid 10129015)
40. Isnansetyo A, Horikawa M, Kamei Y (2001) In vitro anti-methicillin- resistant Staphylococcus aureus activity of 2,4-diacetylphloroglucinol produced by Pseudomonas sp. AMSN isolated from a marine alga. J Antimicrob Chemother 47: 724-725. (Pubitemid 32447675)
41. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, et al. (1999) Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 43: 421-423. (Pubitemid 29079191)
42. Daum RS (2007) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357: 380-390.
43. Schito GC, Debbia EA, Pesce A (1996) Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). The Alexander Project Collaborative Group. J Antimicrob Chemother 38 Suppl A: 97-106.
44. Gilbert M, Boscia JA, Kobasa WD, Kaye D (1986) Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 29: 461-463. (Pubitemid 16143255)
45. Rubin JE, Ball KR, Chirino-Trejo M (2011) Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus pseudintermedius isolated from various animals. Can Vet J 52: 153-157.
46. Pohlod DJ, Saravolatz LD, Somerville MM (1988) In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones. J Antimicrob Chemother 22 Suppl D: 35-41.
47. Al-Abdullah ES (2012) Gatifloxacin. Profiles Drug Subst Excip Relat Methodol 37: 183-243.
48. Zuo GY, Li Y, Han J, Wang GC, Zhang YL, et al. (2012) Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules 17: 10322-10330.
49. Champney WS, Tober CL (2000) Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol 41: 126-135. (Pubitemid 30437606)
50. Clarke AM, Zemcov SJ (1989) Comparative in vitro activity of lomefloxacin, a new difluoroquinolone. Eur J Clin Microbiol Infect Dis 8: 164-168. (Pubitemid 19072652)
51. Bishburg E, Bishburg K (2009) Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 34: 395-401.
52. Alba V, Urban E, Angeles Dominguez M, Nagy E, Nord CE, et al. (2009) In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents 33: 272-275.
53. Walsh TJ, Hansen SL, Tatem BA, Auger F, Standiford HC (1985) Activity of novobiocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 15: 435-440. (Pubitemid 15114327)
54. Smith SM (1986) In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin- resistant Staphylococcus aureus. Antimicrob Agents Chemother 29: 325-326.
55. Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, et al. (1993) In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother 37: 384-392. (Pubitemid 23072577)
56. Sultana Y, Aqil M, Ali A (2005) Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm 55: 305-314. (Pubitemid 41495274)
57. Saravu K, Mukhopadhyay C, Satyanarayanan V, Pai A, Komaranchath AS, et al. (2012) Successful treatment of right-sided native valve methicillin- resistant Staphylococcus aureus endocarditis and septicaemia with teicoplanin and rifampicin: a case report. Scand J Infect Dis 44: 544-547.
58. Schmalreck AF, Kottmann I, Reiser A, Ruffer U, Schlenk R, et al. (1997) Susceptibility testing of macrolide and lincosamide antibiotics according to DIN guidelines. Deutsches Institut fur Normung. J Antimicrob Chemother 40: 179-187. (Pubitemid 27394010)
59. Qadri SM, Ueno Y, Postle G, Tullo D, San Pedro J (1993) Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria. Eur J Clin Microbiol Infect Dis 12: 372-377. (Pubitemid 23184854)
60. Hoogkamp-Korstanje JA (1997) In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against grampositive and gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 40: 427-431.
61. Maple PA, Hamilton-Miller JM, Brumfitt W (1991) Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 35: 345-350.
62. Brun Y, Coulet M, Forey F, Fleurette J (1988) [In vitro activity of roxithromycin compared to 5 other macrolides against staphylococci]. Pathol Biol (Paris) 36: 613-618.
63. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52: e18-55.
64. Martin RJ (1997) Modes of action of anthelmintic drugs. Vet J 154: 11-34.
65. Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, et al. (2010) Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A 107: 3424-3429.
66. Williamson RL, Metcalf RL (1967) Salicylanilides: a new group of active uncouplers of oxidative phosphorylation. Science 158: 1694-1695.
67. Hlasta DJ, Demers JP, Foleno BD, Fraga-Spano SA, Guan J, et al. (1998) Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Bioorg Med Chem Lett 8: 1923-1928. (Pubitemid 28338018)
68. Stock AM, Robinson VL, Goudreau PN (2000) Two-component signal transduction. Annu Rev Biochem 69: 183-215.
69. Beier D, Gross R (2006) Regulation of bacterial virulence by two-component systems. Curr Opin Microbiol 9: 143-152.
70. Stephenson K, Hoch JA (2002) Virulence- and antibiotic resistance-associated two-component signal transduction systems of Gram-positive pathogenic bacteria as targets for antimicrobial therapy. Pharmacol Ther 93: 293-305. (Pubitemid 34615570)
71. Barrett JF, Goldschmidt RM, Lawrence LE, Foleno B, Chen R, et al. (1998) Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci U S A 95: 5317-5322. (Pubitemid 28208595)
72. Watanabe T, Okada A, Gotoh Y, Utsumi R (2008) Inhibitors targeting two-component signal transduction. Adv Exp Med Biol 631: 229-236.
73. Michiels M, Meuldermans W, Heykants J (1987) The metabolism and fate of closantel (Flukiver) in sheep and cattle. Drug Metab Rev 18: 235-251. (Pubitemid 18003736)
74. Hamilton B, Dong Y, Shindo M, Liu W, Odell I, et al. (2005) A systematic RNAi screen for longevity genes in C. elegans. Genes Dev 19: 1544-1555. (Pubitemid 41002998)